CEACAM5 and colorectal carcinoma: Moreover, a subgroup of patients with hypermethylated CEACAM5 promoters that escape from inactivation by DNA methylation demonstrated the molecular and clinical features with a BRAF mutation, TGFB2 mutation, MSI‐H, recurrent peritoneal seeding, and worst prognosis, which may provide new insights into CRC.